Surface-Modified Circuits for Blood Modification
Inventors: Daniel Kohane, Boaz Mizrahi, James McAlvin
Invention Types: Medical Device
Research Areas: Oncology/Hematology
Keywords: Medical Device, Patient Care, PolymerFor More Information Contact: Chou, Jennifer
Sepsis represents an uncontrolled inflammatory response incited by infection. Inflammatory cytokines such as TNF-a, IL-1ß, IL-6, VEGF, and many more have been implicated as the culprits for the sepsis syndrome and its associated features. Attempts to modulate the inflammatory cascade have been largely unsuccessful, including trials of corticosteroids, antiendotoxin antibodies, TNF-a antagonists, IL-1 receptor antagonists, ibuprofen, and extracorporeal blood modification. One reason for their failure may be that the pathophysiology of sepsis syndrome changes over time. The early phase is characterized by a surge of inflammatory cytokines and the later phase shifts toward an immunosuppressive state developing and is mediated by anti-inflammatory cytokines.
Based on the above information, the Kohane laboratory is developing immune-modulating extracorporeal circuits for sepsis that selectively filter deleterious cytokines. These circuits are highly selective and their effect is limited to the time that they are in use (i.e. during the appropriate phase of the sepsis syndrome). To treat the patient, blood is flowed through the device where cytokines are removed and the cleansed blood then flows back into the body.
• Treatment of sepsis (and other inflammatory diseases) through a device that removes cytokines from the blood
• Devices could be adapted to clear bacteria from septicemic patients
• Current treatments of sepsis have seen failures because the pathophysiology of sepsis syndrome changes over time. The early phase is characterized by a surge of inflammatory cytokines and the later phase shifts toward an immunosuppressive state. |
• This device overcomes the pathophysiological changes by offering selective and time-limited binding of target molecules adapted to the appropriate phase of the sepsis syndrome.
Sponsored research or license for development of the therapeutic
IPStatus: Pat. Pend.